Compare Merck & Co., Inc. (MRK) vs Rockwell Automation (ROK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Rockwell Automation — how do they compare? Merck & Co., Inc. trades at $148 (market cap $363.98B), while Rockwell Automation trades at $427.73 (market cap $47.32B). The key difference: Merck & Co., Inc. is far larger — about 7.7× Rockwell Automation's market cap, and Merck & Co., Inc. pays the higher dividend (2.3%). Which is the better fit depends on your goals.
| MRK | ROK | |
|---|---|---|
Market Cap | $363.98B | $47.32B |
Sector | Health | Industrials |
52-Week High | $156.43 | $495.08 |
52-Week Low | $77.60 | $333.75 |
Enterprise Value | $410.75B | $50.45B |
Dividend Yield | 2.3% | 1.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and support near $147. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.22. Revenue reached $65.01B in 2025, and the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline.
Outlook remains positive with a consensus price target of $157, offering ~6% upside. Risks include high P/E of 118.77 and competitive pressures in pharma. Institutional buying and a 67.57% buy rating from analysts support a constructive view, though net income margin of 4.77% warrants monitoring.
Rockwell Automation (ROK) trades at $429.13, down 1.08% on the day, with a bearish technical signal and mixed sentiment. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $3.49 exceeding expectations, but faces declining profit margins from 14.1% in 2023 to 10.41% in 2025. Analyst consensus is a Buy with a $514 price target, though technical indicators show resistance near $434 and support at $427.
The stock offers upside based on analyst targets and robust cash flow, but risks include margin pressure, high valuation multiples, and macroeconomic sensitivity. Institutional interest remains positive with recent investments, but investors should weigh the bearish technical trend against fundamental strengths in industrial automation demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Rockwell Automation
Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →
